Targovax
A phase I/II dose escalation study with expansion cohorts to investigate the safety, biologic and anti-tumor activity of ONCOS-102 in combination with durvalumab in subjects with advanced peritoneal malignancies (NCT02963831)
Dmitriy Zamarin, M.D., Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY
Kunle Odunsi, M.D., Ph.D., Roswell Park Cancer Institute, Buffalo, NY
https://www.cancerresearch.org/scientists/clinical-accelerator/portfolio
https://clinicaltrials.gov/ct2/show/NCT02963831
Dmitriy Zamarin, M.D., Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY
Kunle Odunsi, M.D., Ph.D., Roswell Park Cancer Institute, Buffalo, NY
https://www.cancerresearch.org/scientists/clinical-accelerator/portfolio
https://clinicaltrials.gov/ct2/show/NCT02963831
Redigert 15.12.2018 kl 04:56
Du må logge inn for å svare
Whatsthat
15.12.2018 kl 11:21
1294
Kortsiltg sett og med tanke på potensiell salg/avtaler på ONCOS, så er det denne som virkelig gjelder. ref sist presentasjon... 78 pasienter, sponset allerede :) ;)